New Botox (Allergan Inc) Research From University of Calgary

Clostridium botulinum type A neurotoxin complex – otherwise known as Botox (Allergan, Toronto Canada) – has gained popularity as a cosmetic anti-wrinkle treatment.

It has been marketed for cosmetic use for the prevention of wrinkles in younger people and for the treatment of wrinkles due to aging.  Allergan introduced Botox in 1989 and it was approved by the US FDA for moderate frown lines in 2002.  More information about the history of BOTOX can be found here.

New research from the University of Calgary shows that in their model muscle atrophy was detected far from the injection site.  Information about the study can be found on the University of Calgary website.

As they point out in their article, Botox has non-cosmetic uses in conditions such as cerebral palsy and blepharospasm.  As with any treatment, the risks and benefits need to be well understood and considered carefully before proceeding.  There are studies that document the safety of Botox for cosmetic use, however this new research raises concerns about possible side effects in muscles that are far away from the injection site.  Since Botox is a treatment that will need to be repeated to maintain the effects, it is important for those who are undergoing treatments to be aware of new findings.  Asking your provider about new research will help to make an informed choice each time you are considering a treatment.

This same approach is recommended for people considering laser vision correction.  Surface no-flap PRK has been performed since the 1980’s in North America and has an excellent long term safety record.  Over the past 25 years there have been a number of advances and numerous studies which have improved the safety and results of laser vision correction.

To book a complimentary laser vision correction assessment with Dr. Anderson Penno, contact Western Laser Eye Associates today.